Literature DB >> 9222459

Survival and neonatal and neurodevelopmental outcome of 24-29 week gestation infants according to primary cause of preterm delivery.

P H Gray1, T M Hurley, Y M Rogers, M J O'Callaghan, D I Tudehope, Y R Burns, M Phty, H A Mohay.   

Abstract

A total of 189 infants of 24-29 weeks' gestation were born in a regional perinatal centre during a 2-year period. They were divided into groups according to the primary cause of preterm delivery: antepartum haemorrhage (n = 37, 20%), preeclampsia (n = 27), 14%), preterm premature rupture of membranes (n = 64, 34%), preterm labour (n = 27, 14%), chorioamnionitis (n = 16, 8%), other complications (n = 18, 10%). The perinatal mortality rate (PMR) was 286/1,000 of whom 44% were stillbirths. The 'other complication' group had the highest PMR due to a large number of intrauterine deaths, with no differences in neonatal mortality between the groups. Preeclampsia was associated with an increased risk of necrotizing enterocolitis and chorioamnionitis was associated with an increased risk of periventricular haemorrhage. Follow-up to at least 2 years was performed in 122 (97%) of survivors. Cerebral palsy occurred in 7%, while 18% had neurodevelopmental disability. No relationship was found between primary cause of preterm delivery and outcome. This information should be of value in counselling parents when preterm delivery is imminent.

Entities:  

Mesh:

Year:  1997        PMID: 9222459     DOI: 10.1111/j.1479-828x.1997.tb02245.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  9 in total

Review 1.  Evidence of selection bias in preterm survival studies: a systematic review.

Authors:  D J Evans; M I Levene
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-03       Impact factor: 5.747

Review 2.  Chorioamnionitis in the Development of Cerebral Palsy: A Meta-analysis and Systematic Review.

Authors:  Zhongjie Shi; Lin Ma; Kehuan Luo; Monika Bajaj; Sanjay Chawla; Girija Natarajan; Henrik Hagberg; Sidhartha Tan
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

3.  Long term outcome of twin-twin transfusion syndrome.

Authors:  R B Cincotta; P H Gray; G Phythian; Y M Rogers; F Y Chan
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-11       Impact factor: 5.747

Review 4.  [Treatment of melanoma during pregnancy].

Authors:  L A Schneider
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

5.  Cost of racial disparity in preterm birth: evidence from Michigan.

Authors:  Xiao Xu; Violanda Grigorescu; Kristine A Siefert; Jody R Lori; Scott B Ransom
Journal:  J Health Care Poor Underserved       Date:  2009-08

6.  Chorioamnionitis appears not to be a Risk Factor for Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-Analysis.

Authors:  Elham Behbodi; Eduardo Villamor-Martínez; Pieter L J Degraeuwe; Eduardo Villamor
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

7.  Chorioamnionitis as a risk factor for retinopathy of prematurity: An updated systematic review and meta-analysis.

Authors:  Eduardo Villamor-Martinez; Giacomo Cavallaro; Genny Raffaeli; Owais M M Mohammed Rahim; Silvia Gulden; Amro M T Ghazi; Fabio Mosca; Pieter Degraeuwe; Eduardo Villamor
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

8.  Association of Chorioamnionitis With Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review, Meta-analysis, and Metaregression.

Authors:  Eduardo Villamor-Martinez; María Álvarez-Fuente; Amro M T Ghazi; Pieter Degraeuwe; Luc J I Zimmermann; Boris W Kramer; Eduardo Villamor
Journal:  JAMA Netw Open       Date:  2019-11-01

9.  Chorioamnionitis Is a Risk Factor for Intraventricular Hemorrhage in Preterm Infants: A Systematic Review and Meta-Analysis.

Authors:  Eduardo Villamor-Martinez; Monica Fumagalli; Owais Mohammed Rahim; Sofia Passera; Giacomo Cavallaro; Pieter Degraeuwe; Fabio Mosca; Eduardo Villamor
Journal:  Front Physiol       Date:  2018-09-11       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.